EBV-associated T and NK cell lymphoproliferative disorders: Consensus report of the 4th Asian Hematopathology Workshop

Journal of Hematopathology

Volumn 5, Issue 4, 2012, Pages 319-324

  Ko, Young Hyeh ^a   Kim, Hyun Jung ^b   Oh, Young Ha ^c   Park, Geongsin ^d   Lee, Seung Sook ^e   Huh, Jooryung ^f   Kim, Chul Woo ^g   Kim, Insun ^h   Ng, Siok Bian ⁱ   Tan, Soo Young ^j   Chuang, Shih Sung ^k   Nakamura, Naoya ^l   Yoshino, Tadashi ^m   Nakamura, Shigeo ⁿ   Kimura, Hiroshi ⁿ   Ohshima, Koichi ^o  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Inje University College of Medicine   (South Korea)

^c Hanyang University Guri Hospital   (South Korea)

^d The Catholic University of Korea   (South Korea)

^e Korea Cancer Center Hospital   (South Korea)

^f University of Ulsan College of Medicine   (South Korea)

^g Seoul National University Hospital   (South Korea)

^h Korea University College of Medicine   (South Korea)

ⁱ NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^j SINGAPORE GENERAL HOSPITAL   (Singapore)

^k Chi Mei Medical Centre   (Taiwan)

^l TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^m OKAYAMA UNIVERSITY   (Japan)

ⁿ NAGOYA UNIVERSITY   (Japan)

^o KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Chronic active infection; EBV; Hemophagocytosis; Hydroa vacciniforme; Lymphoproliferative disease

Indexed keywords

EID: 84890251881     PISSN: None     EISSN: 18655785     Source Type: Journal    
DOI: 10.1007/s12308-012-0169-1     Document Type: Article

References (32)

1. Iwatsuki K, Yamamoto T, Tsuji K, Suzuki D, Fujii K, Matsuura H, Oono T (2004) A spectrum of clinical manifestations caused by host immune responses against Epstein-Barr virus infections. Acta Med Okayama 58: 169-180.
2. Cohen JI, Kimura H, Nakamura S, Ko YH, Jaffe ES (2009) Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8-9 September 2008. Ann Oncol 20: 1472-1482.
3. Jones JF, Ray CG, Minnich LL, Hicks MJ, Kibler R, Lucas DO (1985) Evidence for active Epstein-Barr virus infection in patients with persistent, unexplained illnesses: elevated anti-early antigen antibodies. Ann Intern Med 102: 1-7.
4. Chan JKC, Jaffe ES, Ralfkiaer E, Ko YH (2008) Aggressive NK-cell leukaemia. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds) WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. International Agency for Research on Cancer, Lyon, pp 276-277.
5. Chan JKC, Quintanilla-Martinez L, Ferry JA, Peh SC (2008) Extranodal NK/T-cell lymphoma, nasal type. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds) WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. International Agency for Research on Cancer, Lyon, pp 285-288.
6. Kimura H (2006) Pathogenesis of chronic active Epstein-Barr virus infection: is this an infectious disease, lymphoproliferative disorder, or immunodeficiency? Rev Med Virol 16: 251-261.
7. Shibata Y, Hoshino Y, Hara S, Yagasaki H, Kojima S, Nishiyama Y, Morishima T, Kimura H (2006) Clonality analysis by sequence variation of the latent membrane protein 1 gene in patients with chronic active Epstein-Barr virus infection. J Med Virol 78: 770-779.
8. Ohshima K, Kimura H, Yoshino T, Kim CW, Ko YH, Lee SS, Peh SC, Chan JK (2008) Proposed categorization of pathological states of EBV-associated T/natural killer-cell lymphoproliferative disorder (LPD) in children and young adults: overlap with chronic active EBV infection and infantile fulminant EBV T-LPD. Pathol Int 58: 209-217.
9. Okano M, Kawa K, Kimura H, Yachie A, Wakiguchi H, Maeda A, Imai S, Ohga S, Kanegane H, Tsuchiya S, Morio T, Mori M, Yokota S, Imashuku S (2005) Proposed guidelines for diagnosing chronic active Epstein-Barr virus infection. Am J Hematol 80: 64-69.
10. Ohshima K, Suzumiya J, Sugihara M, Nagafuchi S, Ohga S, Kikuchi M (1998) Clinicopathological study of severe chronic active Epstein-Barr virus infection that developed in association with lymphoproliferative disorder and/or hemophagocytic syndrome. Pathol Int 48: 934-943.
11. Kimura H, Hoshino Y, Kanegane H, Tsuge I, Okamura T, Kawa K, Morishima T (2001) Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. Blood 98: 280-286.
12. Quintanilla-Martinez L, Kimura H, Jaffe ES (2008) EBV-positive T-cell lymphoproliferative disorders of childhood. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds) WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. International Agency for Research on Cancer, Lyon, pp 278-280.
13. Quintanilla-Martinez L, Kumar S, Fend F, Reyes E, Teruya-Feldstein J, Kingma DW, Sorbara L, Raffeld M, Straus SE, Jaffe ES (2000) Fulminant EBV(+) T-cell lymphoproliferative disorder following acute/chronic EBV infection: a distinct clinicopathologic syndrome. Blood 96: 443-451.
14. Chuang HC, Lay JD, Chuang SE, Hsieh WC, Chang Y, Su IJ (2007) Epstein-Barr virus (EBV) latent membrane protein-1 down-regulates tumor necrosis factor-alpha (TNF-alpha) receptor-1 and confers resistance to TNF-alpha-induced apoptosis in T cells: implication for the progression to T-cell lymphoma in EBV-associated hemophagocytic syndrome. Am J Pathol 170: 1607-1617.
15. Lay JD, Tsao CJ, Chen JY, Kadin ME, Su IJ (1997) Upregulation of tumor necrosis factor-alpha gene by Epstein-Barr virus and activation of macrophages in Epstein-Barr virus-infected T cells in the pathogenesis of hemophagocytic syndrome. J Clin Invest 100: 1969-1979.
16. Su IJ, Wang CH, Cheng AL, Chen RL (1995) Hemophagocytic syndrome in Epstein-Barr virus-associated T-lymphoproliferative disorders: disease spectrum, pathogenesis, and management. Leuk Lymphoma 19: 401-406.
17. Fox CP, Shannon-Lowe C, Gothard P, Kishore B, Neilson J, O'Connor N, Rowe M (2010) Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults characterized by high viral genome load within circulating natural killer cells. Clin Infect Dis 51: 66-69.
18. Imashuku S, Hibi S, Tabata Y, Itoh E, Hashida T, Tsunamoto K, Ishimoto K, Kawano F (2000) Outcome of clonal hemophagocytic lymphohistiocytosis: analysis of 32 cases. Leuk Lymphoma 37: 577-584.
19. Magana M, Sangueza P, Gil-Beristain J, Sanchez-Sosa S, Salgado A, Ramon G, Sangueza OP (1998) Angiocentric cutaneous T-cell lymphoma of childhood (hydroa-like lymphoma): a distinctive type of cutaneous T-cell lymphoma. J Am Acad Dermatol 38: 574-579.
20. Wu YH, Chen HC, Hsiao PF, Tu MI, Lin YC, Wang TY (2007) Hydroa vacciniforme-like Epstein-Barr virus-associated monoclonal T-lymphoproliferative disorder in a child. Int J Dermatol 46: 1081-1086.
21. Oono T, Arata J, Masuda T, Ohtsuki Y (1986) Coexistence of hydroa vacciniforme and malignant lymphoma. Arch Dermatol 122: 1306-1309.
22. Iwatsuki K, Ohtsuka M, Akiba H, Kaneko F (1999) Atypical hydroa vacciniforme in childhood: from a smoldering stage to Epstein-Barr virus-associated lymphoid malignancy. J Am Acad Dermatol 40: 283-284.
23. Cho KH, Lee SH, Kim CW, Jeon YK, Kwon IH, Cho YJ, Lee SK, Suh DH, Chung JH, Yoon TY, Lee SJ (2004) Epstein-Barr virus-associated lymphoproliferative lesions presenting as a hydroa vacciniforme-like eruption: an analysis of six cases. Br J Dermatol 151: 372-380.
24. Kasahara Y, Yachie A, Takei K, Kanegane C, Okada K, Ohta K, Seki H, Igarashi N, Maruhashi K, Katayama K, Katoh E, Terao G, Sakiyama Y, Koizumi S (2001) Differential cellular targets of Epstein-Barr virus (EBV) infection between acute EBV-associated hemophagocytic lymphohistiocytosis and chronic active EBV infection. Blood 98: 1882-1888.
25. Kimura H, Ito Y, Kawabe S, Gotoh K, Takahashi Y, Kojima S, Naoe T, Esaki S, Kikuta A, Sawada A, Kawa K, Ohshima K, Nakamura S (2012) EBV-associated T/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 cases. Blood 119: 673-686.
26. Ahn JS, Rew SY, Shin MG, Kim HR, Yang DH, Cho D, Kim SH, Bae SY, Lee SR, Kim YK, Kim HJ, Lee JJ (2010) Clinical significance of clonality and Epstein-Barr virus infection in adult patients with hemophagocytic lymphohistiocytosis. Am J Hematol 85: 719-722.
27. Matsuda K, Nakazawa Y, Yanagisawa R, Honda T, Ishii E, Koike K (2011) Detection of T-cell receptor gene rearrangement in children with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis using the BIOMED-2 multiplex polymerase chain reaction combined with GeneScan analysis. Clin Chim Acta 412: 1554-1558.
28. Gu H, Chang B, Qian H, Li G (1996) A clinical study on severe hydroa vacciniforme. Chin Med J (Engl) 109: 645-647.
29. Iwatsuki K, Satoh M, Yamamoto T, Oono T, Morizane S, Ohtsuka M, Xu ZG, Suzuki D, Tsuji K (2006) Pathogenic link between hydroa vacciniforme and Epstein-Barr virus-associated hematologic disorders. Arch Dermatol 142: 587-595.
30. Gupta G, Man I, Kemmett D (2000) Hydroa vacciniforme: a clinical and follow-up study of 17 cases. J Am Acad Dermatol 42: 208-213.
31. Cho KH, Kim CW, Lee DY, Sohn SJ, Kim DW, Chung JH (1996) An Epstein-Barr virus-associated lymphoproliferative lesion of the skin presenting as recurrent necrotic papulovesicles of the face. Br J Dermatol 134: 791-796.
32. Barrionuevo C, Anderson VM, Zevallos-Giampietri E, Zaharia M, Misad O, Bravo F, Caceres H, Taxa L, Martinez MT, Wachtel A, Piris MA (2002) Hydroa-like cutaneous T-cell lymphoma: a clinicopathologic and molecular genetic study of 16 pediatric cases from Peru. Appl Immunohistochem Mol Morphol 10: 7-14.